Sugammadex administration in patients with end-stage renal disease: a narrative review with recommendations

Due to unknown safety concerns, sugammadex should not be administered to patients with end-stage renal disease (ESRD). However, because the supply of benzylisoquinolinium-type neuromuscular blocking agents (NMBAs) has been discontinued, rocuronium is the only non-depolarizing NMBA that can be used i...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Seok Kyeong, Lim, Byung Gun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Anesthesiologists 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902629/
https://www.ncbi.nlm.nih.gov/pubmed/36746897
http://dx.doi.org/10.17085/apm.22259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902629/
https://www.ncbi.nlm.nih.gov/pubmed/36746897
http://dx.doi.org/10.17085/apm.22259

Ejemplares similares